Screener
Doximity DOCS R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Doximity in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Doximity’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001516513-26-000040
| Line item | Three Months Ended June 30, 2026 | 2025 |
|---|---|---|
| Cost of revenue | 23,692 | 15,793 |
| Gross profit | 132,926 | 130,120 |
| Operating expenses: | ||
| Research and development | 38,477 | 26,799 |
| Sales and marketing | 45,049 | 36,365 |
| General and administrative | 15,756 | 12,439 |
| Total operating expenses | 99,282 | 75,603 |
| Income from operations | 33,644 | 54,517 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Doximity's R&D?
- Doximity (DOCS) reported R&D of $38.48M in Q2 2026.
- How has Doximity's R&D changed year-over-year?
- Doximity's R&D increased by 43.6% year-over-year, from $26.8M to $38.48M.
- What is the long-term trend for Doximity's R&D?
- Over 4 years (2022 to 2026), Doximity's R&D has grown at a 20.3% compound annual growth rate (CAGR), from $62.35M to $130.7M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Doximity's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude